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ORIGINAL ARTICLE 
MORBIDITY AND MORTALITY ASSESSMENT IN ACUTE HEPATITIS-E 
Lubna Kamani, Saeed Sadiq Hamid, Faisal Wasim Ismail, Syed Waqas Haider, Safia Awan, 
Ashfaq Ahmed,Wasim Jafri 
Gastroenterology Section, Department of Medicine, Aga Khan University Hospital, Karachi-Pakistan 
Background: Hepatitis-E is an enterically transmitted virus causing acute hepatitis. Mostly it is a 
self-limiting clinical course, but can be life threatening in certain high risk groups. Pakistan is 
endemic for Hepatitis-E with limited published literature. The aim of this study is to evaluate the 
predictors of mortality in patients with acute Hepatitis-E. Methods: We analyzed the medical 
records of 369 adult patients with Hepatitis-E infection admitted at Aga khan University Hospital, 
from January 1996 to December 2010. Details of their laboratory investigations, clinical course 
and complications such as FHF and mortality were noted. The outcome was compared, and 
determinants of mortality were evaluated in important patient subgroups. Results: Out of 369 
patients with Hepatitis-E, 326 (88.3%) were discharged after full recovery. Out of these 22 (6%) 
patients had chronic liver disease CLD in this study, of whom 10 (2.7%) expired (p-value <0.001). 
There were about 67 (18%) pregnant patients, with a mean gestational age of 29.19±7.68 weeks 
and 5 (1.4%) pregnant patients died (p-value=0.23). A total of 58 (15.7%) patients were co-
infected with other hepatotropic virus, and a comparison did not find an increased risk of mortality 
in this group. Conclusion: This study showed that Hepatitis-E is significantly associated with 
mortality in patients suffering from pre-existing chronic liver disease. Pregnancy was not a 
determinant of mortality in Hepatitis-E patients in this study, and neither was co-infection with 
other Hepatotropic viruses. 
Keywords: Acute Hepatitis, Hepatitis-E, Hepatitis. 
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INTRODUCTION 
Hepatitis-E infection is a major form of enterically 
transmitted non-A, non-B Hepatitis. It is the leading 
cause of acute Hepatitis in the world, with the highest 
number of cases reported in the developing regions, 
i.e., Asia, Africa, Central America, and the Middle 
East.1,2 With almost 2.3 billion people affected 
globally,3 Hepatitis-E is an emerging pathogen. The 
virus is responsible for causing several water-borne 
epidemics of acute Hepatitis at a large scale in 
developing countries, where it may also cause 
sporadic cases. About 10–95% of admitted cases of 
Hepatitis in South Asia have been attributed to 
Hepatitis-E alone.4–10 A re-evaluation of the 
epidemiology of the virus indicates a global 
distribution that isn't limited merely to the developing 
world, but with infection occurring due to food borne 
zoonotic transmission in the developed countries.11–14  
Hepatitis-E infection is caused by Hepatitis-
E virus (HEV), which is a single-stranded positive 
sense RNA virus belonging to the Hepeviridae family. 
It is 32–34 nm in diameter, with a genome 
approximately 7200 bases in length. HEV can be 
classified into at least four major genotypes (1–4)15 
with genotype 1 being responsible for most cases of 
epidemic and sporadic Hepatitis-E in the developing 
world. The virus has an incubation of 15–60 days, 
and primarily leads an acute and self-limited course. 
It is transmitted via the feco-oral route, and spread by 
contaminated water in endemic areas. The clinical 
presentation can't be distinguished from other forms 
of acute viral Hepatitis. Asymptomatic infections 
have also been observed, especially in children, who 
show a symptomatic to asymptomatic ratio of 1:12, 
compared to only 1:3 for adults.8 The highest attack 
rates are seen in an age range between 15–40 years.16 
Anti-HEV IgM is used as an acute phase 
marker for the infection, where as anti-HEV IgG is 
used to assess exposure to HEV. The latter studied in 
the healthy population of the developed countries 
shows a range between 9.3–26%, while that in the 
general population of India ranges from 4% in the 
areas of Kashmir and South India to a much higher 
29–35% in Delhi.8,17–19 The number of cases reported 
in the developed world can usually be traced back to 
a history of travel.20 Being an enterically transmitted 
virus, it is shed in large titers in the human feces21, 
which can accumulate in the sewerage that becomes 
an important source of contamination of drinking 
water resources.22 This mode of contamination is a 
common phenomenon in the developing regions of 
the world. Infect, studies from India show an HEV 
prevalence of 41% throughout the year in sewerage 
water23, with as high as 57% of its sewerage workers 
were positive for IgG anti-HEV.24 Data from Pakistan 
is no different, with a study done on samples 
obtained from sewerage water in Rawalpindi and 
Islamabad discovering 40.7% of the sewerage 
samples to be contaminated with HEV.25 
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In addition to its role as a major cause of 
self-limited Hepatitis, the virus possesses certain 
peculiar characteristics in both its clinical course and 
outcome that researchers struggle to understand. A 
crucial association being its aggressive course in 
pregnant women. Various studies from developing 
countries showed an increased incidence of mortality 
in this group, especially in the third trimester.26–30 
Exact cause of increased mortality in pregnant 
patients is unknown but few studies suggested 
progression to Fulminant Hepatic Failure (FHF) and 
obstetric complications as a cause of death,30,31 with a 
mortality that ranges as high as 15–20%32. Also 
documented in this hi-risk category of patients is the 
vertical transmission of HEV, with foetal outcomes 
that range between intrauterine foetal death to 
symptomatic and asymptomatic neonatal hepatic 
infection.33 Interestingly however, this 
disproportionately high incidence of infection and 
mortality that was observed in the pregnant 
population of developing countries such as India was 
not shared by the pregnant population group studied 
in Egypt.34 
Another equally perplexing trait possessed 
by the HEV is the severe morbidity it causes in 
another patient group, i.e., those with pre-existing 
and advanced chronic liver disease. Studies from 
India, also highly endemic for HEV, have 
demonstrated that super-infection with HEV in 
cirrhotics can be complicated by Acute on Chronic 
Liver Failure (ACLF) and mortality.35–38 Other 
studies done on an entirely different set of patients, 
i.e., the immuno-suppressed patients who have 
undergone organ transplant, have suggested that HEV 
may also progress to a chronic course39–41, and can 
cause chronic hepatitis in more than 60% of solid 
organ recipients42 thus again controvert its role as a 
benign self-limiting condition. 
The epidemiological profile of Hepatitis-E 
infection in Pakistan is similar to that witnessed in 
other countries of South Asia, as being endemic and 
leading a benign self-limited clinical course in most 
patients.43,44 Outbreaks have been documented in 
Sargodha46, Abbottabad46,47 and a major epidemic 
that was reported in Islamabad in 1993-1994 owing 
to a malfunctioning water treatment plant that 
affected about  4,000 people48. HEV in Pakistan has 
also been reported to affect pregnant women mostly 
in their third trimester, with majority of the women 
who are young and from the lower economic strata.49 
But despite observations from around the world -and 
not just South Asia- that clearly depict the role of 
HEV as a growing and important problem, there still 
is a significant void in literature from Pakistan on the 
clinical progression and outcome of HEV that varies 
amongst the different patient subgroups infected with 
this disease. In this retrospective cohort study, 
therefore, we delineate the symptoms, clinical course, 
biochemistry indices, complications and mortality of 
HEV in patients treated between 1994 till 2008 at a 
tertiary care hospital in Karachi, Pakistan. Our aim is 
to evaluate the predictors of mortality in various 
patient groups suffering from Hepatitis-E, namely the 
pregnant population, those with pre-existing chronic 
liver disease and those patients who were co infected 
with other hepatotropic viruses. 
MATERIAL AND METHODS 
This is a cross-sectional review of medical records of 
369 patients with Hepatitis-E infection admitted at 
Aga khan University Hospital, from January 1996 to 
December 2010. It was approved by hospital ethics 
committee. We included these patients in our study 
based on a diagnosis of Hepatitis-E made through 
patient’s history, clinical signs and symptoms and 
laboratory workup including Enzyme-linked 
immuno-sorbent assay (ELISA) of Hepatitis-E 
antibodies (IgM) and liver function tests at the time 
of admission. Patients <12 years were excluded from 
the study. Apart from detailed laboratory 
investigation, we also recorded other co morbid 
illnesses (i.e., chronic liver disease (CLD), chronic 
renal failure, diabetes mellitus, ischemic heart disease 
etc.) The presence of a co-existing Hepatitis infection 
owing to other hepatotropic viruses (A, B, C or D) 
was also noted. Length of illness and hospital stay, 
number of readmissions, and any possible 
progression to chronicity were also looked for and 
noted. Pregnancy status of child bearing women was 
confirmed, with maternal and foetal outcome also 
being noted. 
Patients were later on divided into groups 
depending upon outcome, such as uneventful 
recovery, morbidity like Fulminant hepatic failure 
(FHF) or mortality. A comparison was then made 
between the patients in these two outcome groups 
based on their demographic profile, clinical 
parameters and serum laboratory values. The 
outcome was compared, and determinants of 
mortality were evaluated in the following important 
subgroups that were analyzed in the present study: 
patients having CLD; patients who were diagnosed 
with FHF at any time during the course of their 
hospital stay; pregnant patients, and if they were co-
infected with other hepatotropic viruses (A, B, C, D) 
at the time of admission.  
The CLD group was subdivided on the basis 
of their Child Pugh score into Class A, B, and C. We 
defined FHF when there is development of 
encephalopathy and deranged prothrombin time (PT). 
Diagnosis of CLD was made based on ultrasound and 
laboratory findings. The management of all FHF 
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(pregnant or non-pregnant) patients was done in the 
HDU as per standard guidelines. Ethics approval take 
from hospital committee and there is no conflict of 
interest. 
Statistical analysis was performed using the 
SPSS-18.0. A descriptive analysis was done for 
clinical and the other features, and results are 
presented as mean±standard deviation for 
quantitative variables and number (percentage) for 
qualitative variables. For the analysis, χ2 test and 
Fisher’s exact test were used for categorical variables, 
while the independent sample t-test was applied for 
numerical variables. All p-values were two sided and 
considered as statistically significant if <0.05. 
RESULTS 
A total of 369 adult patients diagnosed with 
Hepatitis-E infection were included in this study. 188 
(50.9%) patients were males. The mean age of our 
study group was 32.13±14.27 years; the general 
characteristics of the study group are presented in 
table-1. A total of 326 (88.3%) patients were 
discharged after making a complete recovery, and 43 
(11.7%) patients expired during the course of the 
illness. In the expired group (n=43), there were 5/43 
(11.6%) pregnant patients, 10/43 (23.3%) patients 
suffering from CLD, and 13/43 (30%) patients who 
were co-infected with other hepatotropic viruses. 
FHF was the cause of mortality in 27 (63.0%).  
Laboratory values of discharged and expired patients 
are given in table-2. 
There were 22 (6%) patients suffering from 
CLD in this study, of whom 12 (3.3%) were 
discharged, and the remaining 10 (2.7%) patients 
expired (all patients were having Child Pugh Class C). 
Superinfection with acute Hepatitis-E in CLD 
patients was found to be associated with mortality (p-
value <0.001) as summarized in table-3 
There were about 67 (18%) pregnant 
patients in this study, with a mean gestational age of 
29.19±7.68 weeks. FHF was reported in about 14/67 
(20.9%) pregnant women. About 5 pregnant patients 
expired in the study, all due to FHF. About 30/67 
(45%) pregnant patients had a full-term delivery, 
27/67 (40.3%) patients had a pre-term delivery, 4/67 
(6.0%) suffered a miscarriage and 4/67 (6.0%) 
deliveries resulted in still births. The incidence of an 
onset of Hepatitis-E in pregnancy was not associated 
with increased mortality (p-value=0.23) in this study. 
(Table-4) 
A total of 58 (15.7%) patients were co-
infected with other hepatotropic virus, and a 
comparison between the discharged vs. the expired 
group in this study did not find an increased risk of 
mortality in patients co-infected with other 
hepatotropic viruses without CLD. 
Table-1: General characteristics of study group 
Variables Discharged 
(n=326) 
Expired 
(n=43) 
p-
value 
Age (Years) 31.15±13.5 39.09 ± 17.1 0.005 
Gender: 
Male 
Female 
 
165 (50.6) 
161 (49.4) 
 
23 (53.5) 
20 (46.5) 
0.72 
 
Associated Hepatitis: 
Hepatitis A 
Hepatitis B (HbsAg) 
Hepatitis C 
Hepatitis B& D 
 
8 (2.5) 
26 (8) 
14 (4.3) 
15 (4.6) 
 
0 
6 (14) 
4 (9.3) 
3 (7) 
 
0.18 
0.23 
0.31 
0.86 
Pregnant: 
Pregnant and FHF 
62/161 (38.8) 
0/161 (0) 
5/20 (25) 
5/20 (25) 
0.23 
Chronic Liver Disease 12 (3.7) 10 (23.3) <0.001 
FHF 37 (11.3) 26 (60.5) <0.001 
Table-2: Laboratory values 
 Discharged Expired p-value 
WBC count 14.99±31.9 16.46±11.5 0.76 
Platelet count 270.59±549.01 186.28±140.5 0.32 
BUN 19.58±27.52 28.80±26.71 0.05 
Creatinine 4.89±20.9 2.50±2.7 0.45 
Potassium 8.09±52.36 4.21±0.83 0.63 
Total Bilirubin 
On admission 
Peak  
Last recorded 
 
9.93±11.1 
15.46±12 
6.54±27.8 
 
17.61±15.1 
21.62±11.9 
20.62±12.7 
 
0.002 
0.03 
0.01 
Direct Bilirubin 
On admission 
Peak  
Last recorded 
 
6.35±7.1 
8.83±.2 
4.28±22.1 
 
10.15±66.8 
10.65±7.10 
10.82±8.06 
 
0.003 
0.37 
0.27 
Indirect Bilirubin 
On admission 
Peak  
Last recorded 
 
4.28±22.1 
8.43±17.2 
2.84±10.5 
 
8.31±7.29 
10.05±6.9 
9.04±6.3 
 
0.59 
0.71 
0.03 
SGPT  
On admission 
Peak  
Last recorded 
 
1257.5±1342.1 
1314.15±1248.9 
225.5±446.3 
 
860.23±1020.6 
1153.57±1072.2 
189.33±332.3 
 
0.06 
0.74 
0.70 
AP 
On admission 
Peak  
Last recorded 
 
238.64±253.7 
309.83±317.5 
132.22±84.1 
 
216.95±168.2 
153.0±51.4 
168.53±118.6 
 
0.59 
0.14 
0.20 
SGOT 
On admission 
Peak  
Last recorded 
 
1171.20±1410.9 
1181.91±1074.4 
176.28±377.3 
 
1655.53±2427.4 
1454.40±1780.9 
1028.44±1998.3 
 
0.31 
0.75 
0.23 
GGT 
On admission 
Peak  
Last recorded 
 
158.76±483.0 
220.02±317.2 
98.05±165.4 
 
101.54±108.9 
67.28±24.4 
82.86±106.23 
 
0.49 
0.006 
0.72 
Table-3: Chronic Liver Disease Patients 
Variables Discharged (n=12) 
Expired 
(n=10) p-value 
Age (years) 
Mean Hospital stay  (ds)  
36.75±14.271 
7.08±4.680 
41.70±14.040 
9.30±5.755 
0.42 
0.33 
Chronic Liver Disease 
Child Pugh A 1 (0.3) 0 
Child Pugh B 4 (1.2) 0 
Child Pugh C 7 (2.1) 10 (23.3) 
<0.001 
Spleen 
Normal 179 (88.6) 26 (83.9) 
Enlarged 23 (11.4) 5 (16.1) 0.45 
Portal Vein 
Normal 195 (96.5) 22(71) 
Dilated 7 (3.5) 9 (29) <0.001 
Ascites 
None 165 (82.1) 11(35.5) 
Mild 23 (11.4) 8 (25.8) 
Moderate 10 (5) 10 (32.3) 
Severe 3 (1.5) 2 (6.5) 
<0.001 
Days hospitalized 5.20±5.6 8.91±6.3 <0.001 
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Table-4: Comparing clinical parameters in 
pregnant vs. non-pregnant female patients 
Variables Pregnant Non-pregnant (n=103) p-value 
Age (years) 
FHF 
25.51±5.13 
14 (20.9) 
34.90±14.38 
11 (10.7) 
<0.001 
0.06 
Hospital Stay (Days) 5.72±4.72 5.25±5.10 0.55 
Symptoms 
Fever 
Abdominal pain 
Vomiting 
 
33 (49.3) 
31 (46.3) 
37 (55.2) 
 
73 (70.9) 
77 (74.8) 
82 (79.6) 
 
0.004 
<0.001 
0.001 
Associated Hepatitis 
Hepatitis A 
Hepatitis B (HbsAg) 
(core B) 
Hepatitis C 
Hepatitis B & D 
Diabetes Mellitus 
 
2 (3.0) 
3 (4.5) 
4 (6) 
2 (3) 
1 (50) 
5 (7.5) 
 
2 (1.9) 
6 (5.8) 
2 (1.9) 
1 (1) 
2 (100) 
20 (19.4) 
 
0.77 
0.61 
0.30 
0.36 
0.24 
0.03 
Hypertension 
Mortality 
2 (3) 
5 (7.5) 
16 (15.5) 
11 (10.7) 
0.009 
0.48 
DISCUSSION 
Pakistan is highly endemic for the Hepatitis-E virus, 
Studies report that this benign infection, however, has 
been associated with poor outcomes in a subset of 
patients such as those suffering from CLD35–38, the 
immuno-compromised solid organ organ-transplant 
recipients39–42, and very importantly the pregnant 
population that shows mortality between 15–20%26–
30,32. In the present study, we retrospectively reviewed 
the clinical course of 369 patients admitted with 
Hepatitis-E infection. 
The results of this study found pre-existing 
chronic liver disease to be significantly associated 
with mortality in patients suffering from Hepatitis-E, 
making it the only hi-risk patient group amongst the 
patients reviewed in this study. Interestingly, 
pregnancy was not a determinant of mortality in 
patients infected with Hepatitis-E in this study, and 
neither was co-infection with other hepatotropic 
viruses (A, B, C and D). The results of our study in 
the CLD group to be significantly associated with 
mortality, is consistent with literature. Kumar et al36 
compared 107 cirrhotic patients super infected with 
HEV to 200 (non-cirrhotic) controls. They found 
HEV infection in cirrhotics to be associated with 
rapid hepatic decompensation as well as higher 
mortality, citing HEV positive status to be an 
independent risk factor for mortality in cirrhotics, in 
another study in Nepal also report superinfection with 
HEV to be a significant predictor of morbidity and 
mortality in this group, where they attribute 
hepatorenal syndrome and upper GI bleeding as the 
most common causes of mortality in these patients. 
The mortality in CLD patients which we report in our 
study, however, was due to FHF. 
The finding of a higher sero-prevalence and 
mortality in the pregnant population, who are 
infected with Hepatitis-E virus, is a crucial 
association well-documented consistently in the past 
in various studies through the years. The causes of 
mortality have been attributed to Fulminant Hepatic 
Failure and obstetric complications such as 
haemorrhage.30,31 Incidence of vertical transmission 
to the foetus is also well-established. Khuroo et al, 
investigated foetal outcomes in the pregnant group 
infected with Hepatitis-E, and found that in-utero 
transmission is possible, and is responsible for foetal 
outcomes that range from intrauterine foetal death to 
symptomatic and asymptomatic  neonatal liver 
disease.31 Studies from Karachi, where Hamid SS et 
al.50 evaluated the clinical course along with the 
maternal and foetal outcome in 12 pregnant women 
who presented with FHF, show maternal and foetal 
mortality to be at 16.6% and 50% respectively. 
Interestingly however, the results in the pregnant 
group in the present study, in which 67 pregnant 
patients were compared to 103 non-pregnant patients 
also affected with Hepatitis-E, are not consistent with 
several previous studies23–27 that have consistently 
documented the association between HEV infection 
during pregnancy and mortality. The onset of 
complications such as Fulminant Hepatic Failure and 
the mortality in the pregnant group was not 
significantly increased than in the non-pregnant 
group that we studied. This finding does not support 
literature, with the exception of studies in another 
highly endemic region, i.e., Egypt, where despite the 
high sero-prevalence, HEV-related mortality in 
pregnant women remains negligible. Stoszek et al34 
studied the course of HEV in a cohort of 2,428 
women living in the Nile Delta in Egypt. They 
reported an anti-HEV prevalence to be 84.3%, and 
factors such as older age, large number of siblings, 
lack of soap usage and contact with cats to be 
associated with sero-prevalence. None of the 
pregnant women in this community however, 
demonstrated clinical hepatitis, FHF or mortality. 
They attributed lack of clinical hepatitis in that 
geographical region to early exposure to HEV during 
childhood, and to a different genotype in the 
community which was less virulent than the one 
responsible for the much higher mortality in South 
Asia. Hepatitis-E genotypying were not done in these 
patients which might be one reason for mortality 
difference in pregnant patients. Also difference in the 
sample size between the pregnant and the non-
pregnant patients in the present study could be a 
reason for this. More prospective studies are required 
to evaluate the sero-prevalence and mortality in 
pregnant women with Hepatitis-E are warranted in 
Pakistan, to ascertain if a less virulent strain is indeed 
affecting patients in this region.   
Our study however, did not indicate 
increased mortality in patients who had serological 
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evidence of mixed Hepatotropic viral infection. Our 
results are consistent with the results reported by 
Kumar et al.51 Arora NK et al52 however, found dual 
infection with Hepatitis-E and Hepatitis A to be the 
largest etiological subgroup of acute hepatic failure in 
their study. In the present sample that we evaluated, 
Hepatitis A and E, both of which are transmitted 
feco-orally, did not show significant mortality. 
CONCLUSION 
The study reiterates the role of Hepatitis-E as a 
significant predictor of mortality in patients with 
chronic liver disease. South Asian countries like 
Pakistan and India still remain highly endemic for 
this virus that has caused major epidemics with high 
mortality in cirrhotics and pregnant population. Our 
results did not find an association between HEV 
infection during pregnancy and mortality, and follow-
up prospective studies are required with a larger 
sample size and Hepatitis-E genotyping to evaluate 
the clinical profile in this population. Being a region 
that has remained highly endemic for HEV, we will 
benefit substantially if the safe and effective vaccine 
is incorporated as soon as possible especially, chronic 
liver disease patients and the pregnant patients would 
undoubtedly be most eligible candidates for the 
vaccine. 
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